희귀질환 치료 시장 규모, 점유율, 성장 분석 : 치료 영역별, 약물 유형별, 투여 경로별, 환자 유형별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Rare Disease Treatment Market Size, Share, and Growth Analysis, By Therapeutic Area, By Drug Type, By Route of Administration, By Patient Type, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1663005
리서치사:SkyQuest
발행일:2025년 02월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 희귀질환 치료 시장 규모는 2023년에 1,949억 3,000만 달러로 평가되며, 2024년 2,138억 4,000만 달러에서 2032년에는 4,484억 8,000만 달러로 성장하며, 예측 기간 중(2025-2032년) CAGR은 9.7%로 성장할 전망입니다.
희귀질환 치료제 시장은 개별적으로는 희귀하지만 전 세계 수백만 명에게 영향을 미치는 희귀질환을 치료함으로써 제약산업에서 중요한 역할을 하고 있습니다. 이 시장은 인식의 향상, 유전자 연구의 발전, 혁신적인 치료 전략, 특히 정밀의료의 발전으로 성장하고 있습니다. 유전체학의 발전으로 환자별 유전자 프로파일에 맞는 표적 치료가 가능해졌습니다. 또한 희귀질환 치료제 지정과 같은 지원적인 규제 프레임워크가 제약사의 투자를 촉진하고 있습니다. 학계, 연구기관, 환자 지원 단체의 협력 체계는 연구와 임상시험을 더욱 촉진하고 있습니다. 그럼에도 불구하고 높은 개발 비용과 임상시험 참여자 모집과 같은 장애물이 존재합니다. 이러한 장애물에도 불구하고 시장은 확대될 태세를 보이고 있으며, 그동안 소외되었던 질병에 대한 혁신적인 치료법이 기대되고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
사례 연구
규제 상황
특허 분석
희귀질환 치료 시장 규모 : 치료 영역별
시장 개요
암
근골격계 질환
호흡기질환
심혈관질환
신경질환
혈액학
감염증
대사장애
희귀질환 치료 시장 규모 : 약물 유형별
시장 개요
생물제제
비생물제제
희귀질환 치료 시장 규모 : 투여 경로별
시장 개요
경구
주사
기타
희귀질환 치료 시장 규모 : 환자 유형별
시장 개요
성인용
소아과
희귀질환 치료 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국
온라인 약국
희귀질환 치료 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
AbbVie Inc.(USA)
Actelion Pharmaceuticals Ltd.(Switzerland)
Alexion Pharmaceuticals Inc.(USA)
Bayer AG(Germany)
Bristol Myers Squibb(USA)
Celgene Corporation(USA)
Eisai Co. Ltd.(Japan)
Eli Lilly and Company(USA)
Johnson & Johnson(USA)
Merck & Co. Inc.(USA)
Novartis AG(Switzerland)
Pfizer Inc.(USA)
Roche(Switzerland)
Sanofi S.A.(France)
Takeda Pharmaceutical Company(Japan)
AstraZeneca plc(UK)
Vertex Pharmaceuticals(USA)
Amgen Inc.(USA)
Biogen Inc.(USA)
Gilead Sciences Inc.(USA)
결론과 제안
KSA
영문 목차
영문목차
Global Rare Disease Treatment Market size was valued at USD 194.93 billion in 2023 and is poised to grow from USD 213.84 billion in 2024 to USD 448.48 billion by 2032, growing at a CAGR of 9.7% during the forecast period (2025-2032).
The rare disease treatment market plays a vital role in the pharmaceutical industry by addressing orphan diseases that, while individually rare, collectively impact millions globally. The market is experiencing growth fueled by heightened awareness, advancements in genetic research, and innovative therapeutic strategies, particularly through precision medicine. Breakthroughs in genomics allow for targeted therapies that cater to the unique genetic profiles of patients. Additionally, supportive regulatory frameworks, such as orphan drug designations, encourage investment from pharmaceuticals. Collaborative efforts among academia, research institutions, and patient advocacy organizations further expedite research and clinical trials. Nevertheless, challenges such as high development costs and recruitment in clinical trials pose obstacles. Despite these hurdles, the market is poised for expansion, promising transformative therapies for neglected conditions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rare Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Rare Disease Treatment Market Segments Analysis
Global Rare Disease Treatment Market is segmented by Therapeutic Area, Drug Type, Route of Administration, Patient Type, Distribution Channel and region. Based on Therapeutic Area, the market is segmented into Cancer, Musculoskeletal Conditions, Respiratory Disorders, Cardiovascular Disorders, Neurological Disorders, Hematology, Infectious Diseases and Metabolic Disorders. Based on Drug Type, the market is segmented into Biologics and Non-biologics. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on Patient Type, the market is segmented into Adult and Pediatric. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Rare Disease Treatment Market
A significant factor fueling the Global Rare Disease Treatment market is the increasing investment in research and development aimed at creating innovative therapies for rare diseases. This surge in funding is paving the way for breakthroughs in biotechnology, genomics, and personalized medicine, which are key to unearthing new and effective treatment options. As scientists and researchers harness these advancements, they are not only enhancing our understanding of rare diseases but also facilitating the development of targeted therapies that can significantly improve patient outcomes. This concerted effort underscores the commitment to addressing the unmet medical needs of those affected by rare conditions.
Restraints in the Global Rare Disease Treatment Market
One of the primary challenges facing the Global Rare Disease Treatment market is the substantial financial burden associated with research, clinical trials, and the development of therapies for these conditions. The relatively small patient population complicates the ability to recuperate the high expenses involved, which in turn contributes to elevated drug prices. Consequently, this economic barrier can impede investment in new treatments and limit the availability of affordable options for patients suffering from rare diseases. As a result, the high costs associated with developing effective therapies represent a considerable restraint within the market.
Market Trends of the Global Rare Disease Treatment Market
The Global Rare Disease Treatment market is experiencing a significant trend towards advancements in precision medicine, which is revolutionizing how rare diseases are identified and treated. This evolution allows for the creation of targeted therapies designed to address specific genetic mutations or molecular abnormalities, thereby enhancing treatment efficacy and minimizing adverse effects. As personalized medicine gains traction, stakeholders are increasingly investing in research and development to harness the potential of genetic insights and biomarkers. Such innovations not only promise improved patient outcomes but also ensure a more cost-effective treatment landscape, positioning precision medicine as a cornerstone of future rare disease management strategies.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis
Global Rare Disease Treatment Market Size by Therapeutic Area & CAGR (2025-2032)
Market Overview
Cancer
Musculoskeletal Conditions
Respiratory Disorders
Cardiovascular Disorders
Neurological Disorders
Hematology
Infectious Diseases
Metabolic Disorders
Global Rare Disease Treatment Market Size by Drug Type & CAGR (2025-2032)
Market Overview
Biologics
Non-biologics
Global Rare Disease Treatment Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Injectable
Others
Global Rare Disease Treatment Market Size by Patient Type & CAGR (2025-2032)
Market Overview
Adult
Pediatric
Global Rare Disease Treatment Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Rare Disease Treatment Market Size & CAGR (2025-2032)
North America (Therapeutic Area, Drug Type, Route of Administration, Patient Type, Distribution Channel)
US
Canada
Europe (Therapeutic Area, Drug Type, Route of Administration, Patient Type, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Therapeutic Area, Drug Type, Route of Administration, Patient Type, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Therapeutic Area, Drug Type, Route of Administration, Patient Type, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Therapeutic Area, Drug Type, Route of Administration, Patient Type, Distribution Channel)